牛牛AI助理已提取核心訊息
Avenue Therapeutics, Inc. has officially increased its authorized shares from 75 million to 200 million, as detailed in a recent Form 8-K filing with the SEC. The stockholder consent for this increase was obtained on January 9, 2024, and the Certificate of Amendment was filed with the Delaware Secretary of State on February 20, 2024. This amendment to the company's Third Amended and Restated Certificate of Incorporation is documented in exhibit 3.1 of the report. The company's common stock is traded under the symbol ATXI on the Nasdaq Capital Market.
Avenue Therapeutics, Inc. has officially increased its authorized shares from 75 million to 200 million, as detailed in a recent Form 8-K filing with the SEC. The stockholder consent for this increase was obtained on January 9, 2024, and the Certificate of Amendment was filed with the Delaware Secretary of State on February 20, 2024. This amendment to the company's Third Amended and Restated Certificate of Incorporation is documented in exhibit 3.1 of the report. The company's common stock is traded under the symbol ATXI on the Nasdaq Capital Market.
正如最近向美國證券交易委員會提交的8-K表中所詳述的那樣，Avenue Therapeutics, Inc.已正式將其授權股票從7500萬股增加到2億股。此次增持的股東同意於2024年1月9日獲得，修正證書已於2024年2月20日提交給特拉華州國務卿。對公司第三次修訂和重述的公司註冊證書的修正案記錄在報告的附錄3.1中。該公司的普通股在納斯達克資本市場上交易代碼爲ATXI。
正如最近向美國證券交易委員會提交的8-K表中所詳述的那樣，Avenue Therapeutics, Inc.已正式將其授權股票從7500萬股增加到2億股。此次增持的股東同意於2024年1月9日獲得，修正證書已於2024年2月20日提交給特拉華州國務卿。對公司第三次修訂和重述的公司註冊證書的修正案記錄在報告的附錄3.1中。該公司的普通股在納斯達克資本市場上交易代碼爲ATXI。
有用
沒用